AbbVie (NYSE:ABBV) Issues FY 2026 Earnings Guidance

AbbVie (NYSE:ABBV) updated its FY 2026 earnings guidance on Thursday morning. The company provided EPS guidance of 13.870-14.070 for the period, compared to the consensus estimate of 14.020. The company issued revenue guidance of -.

Analyst Ratings Changes

Several brokerages have recently issued reports on ABBV. JPMorgan Chase & Co. increased their price target on shares of AbbVie from $260.00 to $280.00 and gave the stock an “overweight” rating in a research report on Thursday, July 9th. BMO Capital Markets upped their price objective on AbbVie from $258.00 to $300.00 and gave the stock an “outperform” rating in a research report on Monday, July 13th. UBS Group lifted their target price on AbbVie from $230.00 to $260.00 and gave the company a “neutral” rating in a report on Monday, July 13th. Wolfe Research upgraded AbbVie from a “peer perform” rating to an “outperform” rating and set a $300.00 price target on the stock in a report on Thursday, August 13th. Finally, Sanford C. Bernstein reiterated a “market perform” rating on shares of AbbVie in a research note on Tuesday, June 23rd. Two analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $275.95.

AbbVie Stock Performance

NYSE ABBV traded down $1.03 during trading on Thursday, reaching $260.69. 2,878,300 shares of the company’s stock were exchanged, compared to its average volume of 6,696,391. The stock has a market cap of $460.58 billion, a P/E ratio of 73.64, a price-to-earnings-growth ratio of 1.18 and a beta of 0.29. The company has a 50 day moving average price of $254.23 and a two-hundred day moving average price of $229.67. AbbVie has a 1 year low of $190.75 and a 1 year high of $267.47.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Friday, July 31st. The company reported $3.65 EPS for the quarter, beating analysts’ consensus estimates of $3.61 by $0.04. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The business had revenue of $16.99 billion for the quarter, compared to the consensus estimate of $16.80 billion. During the same quarter in the prior year, the business posted $2.97 EPS. The business’s revenue for the quarter was up 10.2% on a year-over-year basis. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Research analysts forecast that AbbVie will post 14.05 EPS for the current fiscal year.

AbbVie Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th were paid a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 2.7%. The ex-dividend date was Wednesday, July 15th. AbbVie’s dividend payout ratio is currently 195.48%.

Insiders Place Their Bets

In other news, EVP Nicholas Donoghoe sold 32,710 shares of the business’s stock in a transaction that occurred on Friday, August 14th. The shares were sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the completion of the sale, the executive vice president owned 74,430 shares in the company, valued at approximately $18,607,500. The trade was a 30.53% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.06% of the company’s stock.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Etentamig succeeds in Phase 3 trial: AbbVie said its investigational BCMA x CD3 bispecific T-cell engager met both primary endpoints in the CERVINO study for heavily pretreated relapsed/refractory multiple myeloma. Etentamig produced a 74% objective response rate and reduced the risk of disease progression or death by 60% versus standard available therapies. The monthly dosing schedule and low reported rates of cytokine release syndrome could support outpatient use and help the drug compete in the expanding multiple myeloma market. AbbVie Announces Positive Topline Results from the Phase 3 CERVINO Trial
• Positive Sentiment: Apogee acquisition completed: AbbVie finalized its approximately $10.9 billion cash acquisition of Apogee Therapeutics (NASDAQ: APGE), adding late-stage immunology assets including zumilokibart for atopic dermatitis and APG273 for asthma. The deal broadens AbbVie’s post-Humira growth pipeline and strengthens its dermatology and respiratory franchises. AbbVie Completes Acquisition of Apogee Therapeutics
• Positive Sentiment: Core growth remains strong: Analysts highlighted continued momentum from Skyrizi, Rinvoq and neuroscience products, helping offset Humira’s ongoing erosion. AbbVie’s shares are trading above their 50-day and 200-day moving averages, reflecting sustained investor confidence. ABBV Stock Trading Above 50- and 200-Day SMAs
• Neutral Sentiment: AbbVie reaffirmed its 2026 adjusted EPS guidance of $13.87-$14.07 and third-quarter guidance of $3.84-$3.88. Management is scheduled to present at the Morgan Stanley Global Healthcare Conference on September 15.
• Negative Sentiment: The Apogee transaction is expected to dilute earnings in the near term before becoming accretive around 2032. Investors also face continued Humira declines, competitive pressure in oncology and aesthetics, and a crowded multiple myeloma market that could limit etentamig’s eventual commercial opportunity.

Hedge Funds Weigh In On AbbVie

Several large investors have recently bought and sold shares of the stock. Litman Gregory Wealth Management LLC purchased a new position in shares of AbbVie during the fourth quarter worth about $28,000. Imprint Wealth LLC increased its position in AbbVie by 56.2% during the fourth quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock worth $29,000 after buying an additional 45 shares during the period. IFC & Insurance Marketing Inc. purchased a new stake in AbbVie in the fourth quarter valued at approximately $31,000. Quarry LP purchased a new stake in AbbVie in the third quarter valued at approximately $41,000. Finally, Jessup Wealth Management Inc acquired a new stake in shares of AbbVie in the fourth quarter valued at approximately $42,000. Institutional investors and hedge funds own 70.23% of the company’s stock.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.